Cell and gene therapies are reshaping treatment landscapes, demanding specialized infusion protocols.
For these complex, high-stakes procedures, standardized workflows are paramount, impacting both efficiency and patient outcomes.
Research reveals significant process variations across centers, highlighting the need for optimization.
Consider this: facilities thawing products near patient rooms report shorter infusion times.
Strategically designed spaces, robust pre-infusion assessments, and meticulous day-of protocols involving clear communication and identity verification are crucial.
Specialized staff training, including competency in recognizing therapy-specific adverse events like CRS and ICANS, is essential.
Ensuring crash cart readiness with therapy-specific medications and establishing comprehensive long-term monitoring, even in outpatient settings, are vital for these once-in-a-lifetime infusions.
By focusing on these key areas, we can enhance safety and optimize outcomes for patients receiving these revolutionary treatments.
Designing Effective Workflows for Advanced Infusions
Standardized, well-designed workflows are critical for the safe and effective delivery of cell and gene therapies.
Research comparing workflows across multiple academic medical centers reveals significant variation in processes that can impact both efficiency and outcomes 16.
Cell and gene therapies require specialized infusion workflows to ensure safe, efficient, and compliant delivery.
Despite 18 FDA-approved products, day-of infusion protocols remain inconsistently defined, leading to process variability that can compromise outcomes and drive up costs.
Standardized workflows reduce redundancies and minimize administration errors.
Interoperability between smart pumps and EMRs has been shown to improve dosing guardrail compliance by up to 73% and cut IV medication waste costs by $132,000 per year at major centers.
Automated scheduling and real-time capacity analytics further optimize chair utilization, delivering a 28% reduction in staff overtime and as much as 41% shorter patient wait times at partner facilities.
Regulatory considerations for advanced therapy infusion include adherence to FDA’s 21 CFR Part 1271 chain-of-custody and traceability requirements.
This helps ensure product integrity from procurement through administration.
Facility Layout and Infrastructure Considerations
Where thawing occurs profoundly impacts infusion efficiency.
Imagine a scenario: cell therapy products thawed steps away from the patient’s bedside versus a distant lab.
Research highlights that the former significantly shortens the critical “thaw-to-infusion” window.
This proximity minimizes potential delays and stress on these fragile therapies, directly influencing workflow efficiency.
For infusion centers, strategically locating thawing stations near patient rooms translates to streamlined processes, reduced wait times, and ultimately, enhanced patient experience during these pivotal treatments.
This seemingly small detail can yield substantial improvements in the delivery of advanced cell and gene therapies.
- Cell therapy laboratory proximity: On-site labs are necessary when products have short expiration times after thawing unless bedside thawing protocols are implemented 6.
- Dedicated infusion spaces: Given the high acuity and monitoring requirements, dedicated spaces for advanced therapy infusions help streamline workflows and concentrate specialized staff and equipment.
Pre-Infusion Preparation and Assessment
Prior to infusion day, several critical preparations must be completed:
- Patient eligibility verification: Comprehensive assessment of disease status, blood tests, and relevant procedures must be documented 7.
- Infection clearance and prophylaxis: Patients should be screened for active bacterial infections and undergo testing for viral infections including CMV, EBV, HHV-6, HIV, Hepatitis, and adenovirus 7.
- Bridging therapy: Depending on the specific therapy, appropriate cytoreduction or bridging treatments may be required 7.
- Central line placement and verification: Ensuring appropriate vascular access is critical, as cellular products should typically not be infused via PICC lines or infusion pumps due to potential cell damage 8.
Day-of-Infusion Protocols
The actual infusion process requires meticulous coordination between multiple stakeholders.
- Communication protocols: Cell therapy technologists (CTTs) must communicate with nursing staff to confirm patient readiness before initiating product thawing 6.
- Identity verification: Multiple redundant identity checks are essential to maintain chain of custody. This includes verification of patient identity, product documentation, and prescription accuracy 8.
- Product handling: For cryopreserved products, proper thawing techniques are critical. Water bath thawing should be conducted with careful attention to prevent contamination 8.
- Pre-medications: Administration of appropriate pre-medications 30 minutes prior to infusion, with specific attention to avoid steroids for T-cell products unless specifically directed 8.
- Infusion technique: Products should be administered via CVC or appropriate gauge cannula, with specific attention to product-specific requirements 8.
Successful infusion demands meticulous collaboration among cross-functional teams.
First, clear communication protocols between cell therapy technologists (CTTs) and nursing staff ensure patient readiness and thaw initiation; at centers, a hand-off checklist reduces delays and errors.
Identity verification follows a “four-eyes” principle: dual confirmation of patient identifiers, product barcode matching, and cross-check against prescription orders, safeguarding the chain of custody.
Cryopreserved products require thawing in a 37 °C water bath with a 1:1 dilution to prevent osmotic shock.
Premedication protocols administer antihistamines orally 15–30 minutes before infusion to mitigate febrile and allergic reactions, avoiding steroids unless specified.
Finally, infusion via central venous catheters or an 18g peripheral cannula demands strict adherence to product-specific flow rates, monitored continuously for signs of infusion-related events.
Staffing and Training Requirements
Gene and cell therapy infusions are among the most complex workflows in outpatient care, requiring specialized training, precise scheduling, and acuity-based staffing to maintain safety and efficacy.
At leading centers, cell therapy technologists undergo rigorous competency-based instruction and typically complete five to eight supervised infusions under experienced supervision before independent practice (Ref. 6).
Nurses administering CAR-T cells must hold specific immune effector cell therapy certification, ensuring recognition and management of complications such as cytokine release syndrome and ICANS.
To mitigate immediate reaction risks, infusions are scheduled during regular working hours when full multidisciplinary support is available.
Recent multicenter analyses demonstrate that advanced cell therapies routinely score at levels 5–6 on six-point acuity scales, underscoring the need for objective acuity tools in staffing models.
They support FDA compliance while optimizing resource utilization in infusion suites.
Crash-Cart Readiness
Given the significant risk of severe adverse reactions with cell and gene therapies, emergency preparedness is paramount.
The Joint Commission has identified numerous issues with crash cart preparedness that could contribute to patient safety events during emergencies 2.
In high-acuity infusion therapies like CAR-T cell and gene therapy, the risk of life-threatening infusion reactions (e.g., cytokine release syndrome [CRS] or anaphylaxis) makes crash-cart readiness a critical priority.
The Joint Commission’s audits often find missing or expired emergency medications and malfunctioning equipment—common crash cart deficiencies that can dangerously delay care.
Infusion centers administering advanced therapies must stock a full complement of essential emergency medications—such as epinephrine for anaphylaxis—and even specialized antidotes like an IL-6 blocker to treat CAR-T–associated CRS.
They should also have immediate access at all times to oxygen delivery systems, advanced airway management tools, and a defibrillator.
Leading infusion suites enforce rigorous crash cart checks (often daily) and conduct regular mock emergency drills to ensure staff are fully prepared for rapid intervention.
Common Crash Cart Issues
Maintaining crash cart readiness is essential for emergency preparedness, yet several recurring issues can erode response capabilities.
Missing, expired, or damaged medications and supplies can delay critical interventions.
In a Pennsylvania Patient Safety Authority review, 56 incidents involved absent or outdated items over 12 months.
Empty oxygen cylinders and drained batteries on life-saving devices undermine functionality when seconds count.
Unsecured carts locked with cumbersome mechanisms or located behind restricted access create unnecessary barriers for clinicians under stress.
Equipment mis-sizing—whether oversized masks or incompatible IV tubing—risks procedural delays and patient harm (How To Prepare Crash Carts For A Regulatory Survey – Nuvara).
Lastly, inconsistent or perfunctory cart audits allow deficiencies to persist; data suggest that failure to perform daily inspections can leave up to one-third of carts noncompliant with institutional protocols.
Engaging leadership in training and accountability frameworks strengthens consistent safeguards.
Emergency Equipment Requirements
Centers administering cell and gene therapies must stock crash carts with both standard and therapy-specific supplies.
Standard emergency equipment should include functioning suction devices and oxygen delivery systems, a comprehensive airway management set, defibrillators with fully charged batteries, and emergency medications for cardiopulmonary arrests .
These are some “must-haves” in the crash cart:
For CAR T-cell infusions, carts must also carry tocilizumab to counter cytokine release syndrome at the first sign of fever or hypotension.
High-dose methylprednisolone (1 g IV daily) for severe or refractory CRS and immune effector cell–associated neurotoxicity syndrome.
Also, anti-epileptic agents, such as levetiracetam, to prevent or manage neurotoxicity-related seizures (CRS and ICANS Grading, Monitoring, & Management).
These items should be clearly labeled and readily accessible in all infusion suites to expedite retrieval during crises.
Regular inventory checks and drills reinforce proficiency and reduce response times.
Staff Preparation
Staff readiness extends beyond equipment checks; a robust training framework empowers clinicians to recognize and promptly manage therapy-specific emergencies.
Recognition training should encompass didactic sessions, case-based workshops, and competency assessments focused on early identification of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS).
CRS can present with fever, hypotension, and hypoxia akin to neutropenic sepsis.
ICANS is characterized by cognitive disturbances and seizures (Managing CRS and ICANS: Approaches and Protocols).
Staff training should teach how to recognize early signs of CRS and Immune ICANS.
CRS can cause fever, low blood pressure, and low oxygen, similar to neutropenic sepsis.
ICANS can cause confusion and seizures.
This training should include lessons, practice scenarios, and tests.
Recognition training should include instruction, practical exercises, and evaluations for the timely detection of CRS.
Response protocols must be codified into clear, stepwise algorithms aligned with ASTCT grading criteria, readily accessible via pocket cards and electronic order sets, reviewed quarterly, and reinforced through annual competency assessments to ensure staff accountability (How I treat adverse effects of CAR-T cell therapy – ESMO Open).
Clear, step-by-step emergency response guides are necessary. These protocols should follow ASTCT grading standards.
They should be easily accessible as pocket cards and in electronic health records.
Regularly reviewing these protocols quarterly and conducting annual competency checks will help ensure staff understand and follow them.
Incorporating regular drills—high-fidelity simulations of CRS and ICANS scenarios—helps teams practice time-sensitive interventions, streamline role responsibilities, and identify latent workflow barriers.
Finally, establishing rapid notification systems through dedicated hotlines, overhead paging, or secure messaging ensures immediate mobilization of specialized personnel.
This approach minimizes delays in escalated care and supporting shared situational awareness.
Long-Term Monitoring for High-Acuity Infusions
Gene and cell therapies represent a breakthrough in precision medicine, offering transformative potential for patients.
However, their complexity demands a significant shift in how adverse events and long-term outcomes are managed.
Unlike traditional therapies, these “living drugs,” such as CAR-T cells, can trigger delayed toxicities like cytokine release syndrome, neurotoxicity, or even insertional oncogenesis.
Sometimes these issues don’t emerge until weeks, months, or years post-infusion.
This complexity necessitates robust, longitudinal monitoring strategies to safeguard patients effectively.
Equally critical is the need to track durable response markers, such as B-cell aplasia or engineered cell persistence, ensuring therapies continue delivering benefits over time.
To meet these challenges, infusion centers must establish advanced frameworks, including standardized late-effect screenings, interoperable registries, and patient-reported outcomes tools.
These systems are essential to protect patients while gathering crucial real-world evidence to shape the future of advanced therapeutics.
Monitoring for CAR-T Therapy-Specific Adverse Events
CAR-T cell therapy has revolutionized oncology, offering hope to patients with otherwise treatment-resistant cancers.
However, its success comes with the need for close monitoring of significant complications.
Particularly, Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).
CRS, the most common side effect, typically manifests within the first month post-infusion.
Its hallmark symptoms include high fever, flu-like symptoms, hypotension, tachycardia, hypoxia, and gastrointestinal distress.
In severe cases, organ dysfunction may occur, requiring rapid intervention.
Equally concerning is ICANS, which can develop alongside CRS or emerge weeks later.
Neurological symptoms such as confusion, seizures, or even cerebral edema demand prompt evaluation.
Early detection is critical.
Incorporating routine monitoring for neurological changes and laboratory markers like elevated CRP or liver enzymes can mitigate risks.
Proactive management strategies ensure patients benefit from CAR-T’s potential while minimizing adverse outcomes.
Tracking Vector Distribution for AAV Therapies
For AAV gene therapies, particularly those delivered intrathecally, monitoring vector distribution and clearance provides critical information:
- Initial distribution assessment: Real-time MRI with gadolinium-based contrast agents can visualize infusate distribution patterns immediately after administration. Different delivery routes result in distinct distribution patterns that affect therapeutic efficacy 3.
- Kinetics monitoring: Analyzing the clearance kinetics of vectors from cerebrospinal fluid provides insights into expected therapeutic durability and potential need for redosing 3.
- Long-term efficacy measures: Disease-specific outcome metrics must be tracked over extended periods to assess the durability of therapeutic response.
Outpatient Monitoring Considerations
As CAR-T cell therapies expand into outpatient settings, maintaining robust monitoring systems is critical to ensure patient safety.
A cornerstone of this approach is patient education.
Individuals must clearly understand the delayed symptoms that signal complications, such as fever or neurological changes, and the importance of seeking immediate medical attention if these occur.
For example, patients should be instructed to return to the hospital at the first sign of feeling unwell, as early intervention can prevent escalation.
Equally essential is establishing seamless communication protocols.
Patients need access to a dedicated care team familiar with CAR-T therapy complications, including 24/7 clinician availability to address urgent concerns.
This proactive communication bridges the gap between outpatient care and hospital-level oversight.
Incorporating remote monitoring tools also elevates safety.
Digital health technologies, such as wearable devices that track vital signs or mobile apps for symptom reporting, provide real-time insights, enabling early detection of adverse events.
Summary
The integration of gene and cell therapies marks a transformative milestone in modern healthcare, demanding a reimagining of how care is delivered.
These groundbreaking treatments require not only specialized workflows but also robust emergency preparedness protocols and extended patient monitoring to manage their complex nature.
Unlike traditional therapies, gene and cell treatments often involve intricate administration processes, necessitating trained staff and advanced infrastructure to mitigate risks and ensure positive patient outcomes.
As these therapies become more prevalent, creating standardized best practices is critical to fostering both safety and efficiency.
For example, workflows at experienced centers have highlighted opportunities to refine processes, from streamlining patient eligibility assessments to enhancing communication between multidisciplinary teams.
These insights pave the way for broader adoption at hospitals and infusion centers, particularly those that may not yet have the resources or expertise to deliver these therapies confidently.
Acuity-based staffing ensures the right expertise is available to manage these challenges, reducing the burden on staff while maintaining high standards of patient care.
Investments in specialized staff training, infrastructure upgrades, and long-term monitoring systems will be crucial for infusion centers aiming to deliver these therapies effectively.
For instance, training programs that equip nurses and support staff to recognize and manage potential adverse events can significantly enhance patient safety.
By embracing these innovations and fostering collaboration across healthcare institutions, gene and cell therapies can be safely integrated into routine care, ultimately transforming the lives of patients with conditions once deemed untreatable.
References
- https://pubmed.ncbi.nlm.nih.gov/33531267/
- https://www.jointcommission.org/resources/news-and-multimedia/newsletters/newsletters/quick-safety/quick-safety-issue-32-crashcart-preparedness/crashcart-preparedness/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6330508/
- https://www.ebmt.org/sites/default/files/migration_legacy_files/document/Cellular%20Therapy%20Manual.pdf
- https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e13553
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9013238/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9263804/
- https://www.theattcnetwork.co.uk/wp-content/uploads/2023/02/WRD-5-INFUSION-OF-CELLULAR-PRODUCTS-combined.pdf
- https://www.sciencedirect.com/science/article/abs/pii/S1465324920309877
- https://www.thermofisher.com/us/en/home/clinical/cell-gene-therapy/gene-therapy/development-workflow.html
- https://www.synthego.com/workflows/cell-gene-therapy
- https://www.eppendorf.com/product-media/doc/en/9802348/Fermentors-Bioreactors_Publication_Bioprocess_Optimizing-Cell-Gene-Therapy-Workflows.pdf
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7339923/
- https://www.oncologynurseadvisor.com/news/infusion-center-acuity-tools-outpatient-treatment-risk/
- https://www.clinicalkey.com
- https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/achieving-car-t-cell-therapy-health-system-readiness
- https://www.sciencedirect.com/science/article/pii/S232905011930066X
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8046110/
- https://www.beckershospitalreview.com/hospital-management-administration/evaluating-four-patient-assignment-strategies-in-infusion-centers
- https://www.cancersupportcommunity.org/sites/default/files/fsac/CAR_T_Patient_and_Caregiver_Guide.pdf
